GeoVax Labs, Inc. New (GOVX) — Analysis Summary
GeoVax Labs, Inc. New (GOVX) has a market cap of $2.57M with year-over-year revenue growth of -37.1%. Net margin stands at -862.3%. The stock trades at a P/E ratio of -0.1.
Key Takeaways
- Revenue changed -37.1% year-over-year
- Net margin of -862.3%
- P/E ratio of -0.1
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, GOVX posted revenue growth of -37.1% and trades at a P/E of -0.1.
GeoVax Labs, Inc. New (GOVX)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Revenue fell 100.0% vs the prior period.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
19
Headquarters
SMYRNA, GA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.